CSF1R and Miyoshi myopathy: In vivo, the administration of the anti CSF-1 receptor antibody CS7 significantly reduced the MM tumor burden, while the in vitro administration of low-dose CS7 could contribute to TAM polarization towards an M1 subtype [110].